PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM
To explore Progression-Free-Survival(FPS) of PULSAR(personalized ultrafractionated stereotactic adaptive radiotherapy) combined with PD-1 Ab and Chemotherapy plus Bevacizumabfor CRLM
Colorectal Cancer Liver Metastasis
RADIATION: Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy|DRUG: Bevacizumab|DRUG: Capecitabine|DRUG: Oxaliplatin|DRUG: Sintilimab
Progression-free-Survival, From enrollment to 36 month
Adverse Reactions, From enrollment to 36 month|Overall Survival (OS), From enrollment to 36 month|Objective Response Rate (ORR), From enrollment to 36 month
To explore Progression-Free-Survival(FPS) of PULSAR(personalized ultrafractionated stereotactic adaptive radiotherapy) combined with PD-1 Ab and Chemotherapy plus Bevacizumabfor CRLM